Methylselenol, a selenium metabolite, induces cell cycle arrest in G1 phase and apoptosis via the extracellular-regulated kinase 1/2 pathway and other cancer signaling genes

Journal of Nutrition

Volumn 139, Issue 9, 2009, Pages 1613-1618

  Zeng, Huawei ^a   Wu, Min ^b   Botnen, James H ^a  

^a GRAND FORKS HUMAN NUTRITION RESEARCH CENTER   (United States)

^b UNIVERSITY OF NORTH DAKOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCL2 RELATED PROTEIN A1; CELL ADHESION MOLECULE; CYCLIN DEPENDENT KINASE INHIBITOR 1C; HEME OXYGENASE 1; MESSENGER RNA; METHYLSELENOL; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P53; SELENIUM; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GENE; GENE CONTROL; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; METABOLITE; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PPAR GAMMA GENE; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THROMBOCYTE; TUMOR CELL; WESTERN BLOTTING; ZINC FINGER PROTEIN GENE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FIBROSARCOMA; G1 PHASE; GENE EXPRESSION; HUMANS; LYASES; METHANOL; METHIONINE; MITOGEN-ACTIVATED PROTEIN KINASE 1; ORGANOSELENIUM COMPOUNDS; RNA, MESSENGER; SELENIUM; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

ERINACEIDAE;

EID: 69549116658     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.109.110320     Document Type: Article

References (43)

1. Lu J, Jiang C. Antiangiogenic activity of selenium in cancer chemoprevention: metabolite-specific effects. Nutr Cancer. 2001;40:64-73. (Pubitemid 34037516)
2. Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr. 1998;128:1845-1854 (Pubitemid 28509845)
3. Zeng H, Combs GF Jr. Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J Nutr Biochem. 2008;19:1-7. (Pubitemid 350213396)
4. Clark LC, Combs GF Jr., Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996;276:1957-1963
5. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM Jr, Kristal AR, Santella RM, Probstfield JL, Moinpour CM, et al. Designing the selenium and vitamin E cancer prevention trial (SELECT). J Natl Cancer Inst. 2005;97:94-102. (Pubitemid 40277089)
6. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers. JAMA. 2009;301:39-51.
7. Ganther HE. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis. 1999;20:1657-1666
8. Combs GF Jr, Gray WP. Chemopreventive agents: selenium. Pharmacol Ther. 1998;79:179-192
9. Miki K, Xu M, Gupta A, Ba Y, Tan Y, Al-Refaie W, Bouvet M, Makuuchi M, Moossa AR, et al. Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. Cancer Res. 2001;61:6805-6810 (Pubitemid 32896504)
10. Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc. 2005;64:527-542 (Pubitemid 41705454)
11. Zeng H, Briske-Anderson M, Idso JP, Hunt CD. The selenium metabolite methylselenol inhibits the migration and invasion potential of HT1080 tumor cells. J Nutr. 2006;136:1528-1532 (Pubitemid 43765357)
12. Esaki N, Tanaka H, Uemura S, Suzuki T, Soda K. Catalytic action of Lmethionine gamma-lyase on selenomethionine and selenols. Biochemistry. 1979;18:407-410
13. Wang Z, Jiang C, Lu J. Induction of caspase-mediated apoptosis and cell-cycle G1 arrest by selenium metabolite methylselenol. Mol Carcinog. 2002;34:113-120 (Pubitemid 34747321)
14. Zhao R, Domann FE, Zhong W. Apoptosis induced by selenomethionine and methioninase is superoxide mediated and p53 dependent in human prostate cancer cells. Mol Cancer Ther. 2006;5:3275-3284 (Pubitemid 46092071)
15. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods. 2001;25:386-401. (Pubitemid 34164011)
16. Jiang C, Wang Z, Ganther H, Lu J. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res. 2001;61:3062-3070 (Pubitemid 32691955)
17. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994;124:619-626 (Pubitemid 24064472)
18. Nyormoi O, Mills L, Bar-Eli M. An MMP-2/MMP-9 inhibitor, 5a. enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ. 2003;10:558-569 (Pubitemid 36656645)
19. Kargiotis O, Chetty C, Gondi CS, Tsung AJ, Dinh DH, Gujrati M, Lakka SS, Kyritsis AP, Rao JS. Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma. Oncogene. 2008;27:4830-4840
20. Lee MH, Reynisdottir I, Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 1995;9:639-649
21. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ. p57KIP2, a structurally distinct member of the p21CIP1 cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 1995;9:650-662
22. KIP2 induces prostate cancer in the mouse. Cancer Res. 2008;68:3601-3608
23. Jozkowicz A, Was H, Dulak J. Heme oxygenase-1 in tumors: is it a false friend? Antioxid Redox Signal. 2007;9:2099-2118
24. Newman PJ, Berndt MC, Gorski J, White GC II, Lyman S, Paddock C, Muller WA. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science. 1990;247:1219-1222 (Pubitemid 20102483)
25. Bergom C, Goel R, Paddock C, Gao C, Newman DK, Matsuyama S, Newman PJ. The cell-adhesion and signaling molecule PECAM-1 is a molecular mediator of resistance to genotoxic chemotherapy. Cancer Biol Ther. 2006;5:1699-1707 (Pubitemid 46256652)
26. Bergom C, Gao C, Newman PJ. Mechanisms of PECAM-1-mediated cytoprotection and implications for cancer cell survival. Leuk Lymphoma. 2005;46:1409-1421 (Pubitemid 41479582)
27. Krishnan A, Nair SA, Pillai MR. Biology of PPAR gamma in cancer: a critical review on existing lacunae. Curr Mol Med. 2007;7:532-540 (Pubitemid 47618050)
28. Vogler M, Dinsdale D, Dyer MJS, Cohen GM. Bcl-2 inhibitors: small molecules with big impact on cancer therapy. Cell Death Differ. 2009;16:360-367
29. Rasooly R, Schuster GU, Gregg JP, Xiao JH, Chandraratna RAS, Stephensen CB. Retinoid X receptor agonists increase Bcl2a1 expression and decrease apoptosis of naive T lymphocytes. J Immunol. 2005;175:7916-7929 (Pubitemid 41798352)
30. Abe Y, Oda-Sato E, Tobiume K, Kawauchi K, Taya Y, Okamoto K, Oren M, Tanaka N. Hedgehog signaling override p53-mediated tumor suppression by activating Mdm2. Proc Natl Acad Sci USA. 2008;105:4838-4843 (Pubitemid 351753833)
31. Olsen CL, Hsu PP, Glienke J, Rubanyi GM, Brooks AR. Hedgehog-interacting protein is highly expressed in endothelial cells but downregulated during angiogenesis and in several human tumors. BMC Cancer. 2004;4:43. (Pubitemid 40180243)
32. Hu Z, Bonifas JM, Aragon G, Kopelovich L, Liang Y, Ohta S, Israel M, Bickers DR, Aszterbaum M, et al. Evidence for lack of enhanced hedgehog target gene expression in common extracutaneous tumors. Cancer Res. 2003;63:923-928 (Pubitemid 36278420)
33. Prahl M, Vilborg A, Palmberg C, Jornvall H, Asker C, Wiman KG. The p53 target protein Wig-1 binds hnRNP A2/B1 and RNA helicase A via RNA. FEBS Lett. 2008;582:2173-2177
34. Jackson MI, Combs GF Jr. Selenium and anticarcinogenesis: underlying mechanisms. Curr Opin Clin Nutr Metab Care. 2008;11:718-726
35. Zeng H. Selenium as an essential micronutrient: roles in cell cycle and apoptosis. Molecules. 2009;14:1263-1278
36. Hoshino R, Tanimura S, Watanabe K, Kataoka T, Kohno M. Blockade of the extracellular signal-regulated kinase pathway induces marked G1 cell cycle arrest and apoptosis in tumor cells in which the pathway is constitutively activated. J Biol Chem. 2001;276:2686-2692
37. Meloche S, Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 2007;26:3227-3239 (Pubitemid 46763017)
38. Jones SM, Kazlauskas A. Growth-factor-dependent mitogenesis requires two distinct phases of signaling. Nat Cell Biol. 2001;3:165-172 (Pubitemid 32118370)
39. Goulet AC, Chigbrow M, Frisk P, Nelson MA. Selenomethionine induces sustained ERK phosphorylation leading to cell-cycle arrest in human colon cancer cells. Carcinogenesis. 2005;26:109-117 (Pubitemid 40207705)
40. Reid ME, Stratton MS, Lillico AJ, Fakih M, Natarajan R, Clark LC, Marshall JR. A report of high dose selenium supplementation: response and toxicities. J Trace Elem Med Biol. 2004;18:69-74. (Pubitemid 39285967)
41. Diplock AT. Indexes of selenium status in human populations. Am J Clin Nutr. 1993;57:S256-8.
42. Ip C, Birringer M, Block E, Kotrebai M, Tyson JF, Uden PC, Lisk DJ. Chemical speciation influences comparative activity of selenium-enriched garlic and yeast in mammary cancer prevention. J Agric Food Chem. 2000;48:2062-2070 (Pubitemid 30431189)
43. Hatfield DL, Gladyshev VN. The outcome of Selenium And Vitamin E Cancer Prevention Trial (SELECT) reveals the need for better understanding of selenium biology. Mol Interv. 2009;9:18-21.